Breakthrough in breast cancer treatment with FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu) for HER2-low and HER2-ultralow metastatic breast cancer.
How a retracted nanoparticle study advanced HER2+ breast cancer treatment through targeted drug delivery concepts